Actoxumab
Actoxumab' is a human monoclonal antibody specifically engineered for the prevention of recurrence of infections caused by Clostridium difficile, a bacterium responsible for significant morbidity and mortality, particularly in the healthcare setting. Actoxumab represents a targeted approach in the battle against this challenging healthcare-associated infection.
Pronunciation
Ak-tox-oo-mab
Development and Trials
Actoxumab's development journey involved collaboration between Medarex Inc., a biopharmaceutical company specializing in monoclonal antibody therapies, and MassBiologics, a non-profit organization and an operating division of the University of Massachusetts Medical School. This partnership successfully advanced Actoxumab through Phase II efficacy trials, demonstrating its potential in clinical settings.
Subsequently, the project was licensed to Merck & Co., Inc., a global healthcare leader, for further development and potential commercialization. This transition marked a significant step towards making Actoxumab available for clinical use, emphasizing the importance of collaboration between academic institutions and the pharmaceutical industry in bringing new therapies to market.
Comparison with Bezlotoxumab
During its clinical evaluation, Actoxumab was compared to bezlotoxumab, another monoclonal antibody developed to target Clostridium difficile infections by neutralizing toxin B produced by the bacteria. Studies revealed that, while both drugs showed promise in preventing recurrence of C. difficile infections, Actoxumab was found to be less effective than Bezlotoxumab. This finding highlights the complexities and challenges in developing targeted therapies and underscores the critical need for continued research and innovation in the treatment of infectious diseases.
Clinical Significance
The development of Actoxumab contributes to the growing field of monoclonal antibody therapies, offering a novel approach to preventing Clostridium difficile infections. Despite the challenges faced in its clinical trials, Actoxumab's journey underscores the importance of targeted therapies in combating antibiotic-resistant infections and the potential for monoclonal antibodies to play a significant role in infectious disease prevention.
Related Terms
- Monoclonal Antibody
- Clostridium difficile Infection
- Antibiotic Resistance
- Infectious Disease
- Pharmaceutical Industry
See Also
External links
- Medical encyclopedia article on Actoxumab
- Wikipedia's article - Actoxumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski